IMUX IMMUNIC, INC.

NEUTRAL Impact: 4/10 8-K
Horizon days Filed Apr 23, 2026 Processed 1mo ago SEC 0001193805-26-000495
8-K context-dependent: Items 3.03, 8.01
Latest settled — T+20d ⚠ clustered
IMUX ▲ +25.82% at T+20d
NEUTRAL call ✓ call won +25.82% · α vs SPY +21.18% · entry $9.18 → $11.55
Next anchor: T+60d in 6w
Currently $12.26 · +33.55% from $9.18 entry
Entry anchored
Apr 22, 03:59 PM ET
via Databento tick
T+1d
-4.14%
call -4.14% · α -4.92%
$8.80
settled 7w ago
T+5d
+9.26%
call +9.26% · α +7.78%
$10.03
settled 6w ago
T+20d
+25.82%
call +25.82% · α +21.18%
$11.55
settled 20d ago
T+60d
call — · α —
in 6w

Price Chart

Loading chart...

Executive Summary

Immunic, Inc. (IMUX) announced a 1-for-10 reverse stock split effective April 27, 2026, reducing its outstanding shares from approximately 136 million to 13.6 million. The move is intended to meet contractual obligations under a prior securities purchase agreement.

Actionable Insight

Monitor trading activity around the new share structure starting April 27, 2026, and assess whether the company meets its contractual obligations under the February 12, 2026 securities purchase agreement.

Key Facts

  • Immunic, Inc. executed a 1-for-10 reverse stock split effective April 27, 2026
  • Outstanding shares reduced from ~136 million to ~13.6 million
  • The reverse split was approved by shareholders on April 14, 2026, and filed with Delaware on April 22, 2026
  • The action is primarily intended to meet contractual obligations under a securities purchase agreement dated February 12, 2026
  • No fractional shares will be issued; holders of fractional shares will receive cash proceeds from the sale of aggregated shares

Financial Impact

Reduces outstanding shares from ~136 million to ~13.6 million; no change to market cap or authorized shares

shares outstandingshare price

Risk Factors

  • Potential negative market perception of reverse splits as a sign of financial distress
  • Liquidity concerns if trading volume does not adjust proportionally to the reduced share count

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193805-26-000495
Document: e665386_ex99-1.htm0001193805-26-000495
Document: e665386_ex3-1.htm0001193805-26-000495
Document: 0001193805-26-000495-index-headers.html0001193805-26-000495
Document: 0001193805-26-000495-index.html0001193805-26-000495
Document: 0001193805-26-000495.txt0001193805-26-000495
7 reports for IMUX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for IMUX — sortable, filterable
Type Now
May 19, 2026
21d ago
3
NEUTRAL ★ 2/10
$11.55 $14.97▲ +29.61%▲ +27.81%$12.26 (+6.15%)
May 19, 2026
21d ago
8-K
NEUTRAL ★ 3/10
$11.60 $14.00▲ +20.69%▲ +18.39%$12.26 (+5.69%)
Apr 30, 2026
5w ago
S-3/A
BEARISH ★ 8/10
$9.65 $11.75▼ −21.76%▼ −19.41%$12.26 (−27.05%)
Apr 23, 2026
6w ago
8-K
NEUTRAL ★ 4/10
$9.18 $10.03▲ +9.26%▲ +7.78%$12.26 (+33.55%)
Apr 14, 2026
8w ago
8-K
NEUTRAL ★ 4/10
$11.10 $9.00▼ −18.92%▼ −20.56%$12.26 (+10.45%)
Apr 10, 2026
8w ago
8-K
NEUTRAL ★ 3/10
$12.20 $9.55▼ −21.72%▼ −25.02%$12.26 (+0.49%)
Feb 26, 2026
14w ago
8-K
BULLISH ★ 8/10
$9.48 $11.10▲ +17.09%▲ +18.22%$12.26 (+29.32%)
Showing 7 of 7

US Market Status

Market Closed — Opens Thu (9h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access